Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 2;6(4):e15103.
doi: 10.2196/15103.

Remote Patient Monitoring in Adults Receiving Transfusion or Infusion for Hematological Disorders Using the VitalPatch and accelerateIQ Monitoring System: Quantitative Feasibility Study

Rik Paulus Bernardus Tonino #  1   2   3 , Karen Larimer  4 , Okke Eissen  1 , Martin Roelof Schipperus  1   2   5
Affiliations

Remote Patient Monitoring in Adults Receiving Transfusion or Infusion for Hematological Disorders Using the VitalPatch and accelerateIQ Monitoring System: Quantitative Feasibility Study

Rik Paulus Bernardus Tonino et al. JMIR Hum Factors. .

Abstract

Background: Frequent vital sign monitoring during and after transfusion of blood products and certain chemotherapies or immunotherapies is critical for detecting infusion reactions and treatment management in patients. Currently, patients return home with instructions to contact the clinic if they feel unwell. Continuous monitoring of vital signs for hematological patients treated with immunotherapy or chemotherapy or receiving blood transfusions using wearable electronic biosensors during and post treatment may improve the safety of these treatments and make remote data collection in an outpatient care setting possible.

Objective: This study aimed to evaluate patient experiences with the VitalPatch wearable sensor (VitalConnect) and to evaluate the usability of data generated by the physIQ accelerateIQ monitoring system for the investigator and nurse.

Methods: A total of 12 patients with hematological disorders receiving red blood cell transfusions, an intravenous (IV) proteasome inhibitor, or an IV immunotherapy agent were included in the study and wore the VitalPatch for 12 days. Patients completed questionnaires focusing on wearability and nurses completed questionnaires focusing on the usability of the VitalPatch.

Results: A total of 12 patients were enrolled over 9 months, with 4 receiving red blood cell transfusions, 4 receiving IV proteasome inhibitors, and 4 receiving IV immunotherapy. These patients were treated for diseases such as multiple myeloma, myelodysplastic syndrome, and non-Hodgkin lymphoma. Of these patients, 83% (10/12) were aged 60 years and older. A total of 4 patients (4/12, 33%) withdrew from the study (3 because of skin irritation and 1 because of patch connection issues). Patients wore biosensor patches at baseline and for 1-week post administration. Patient-reported outcomes (PROs) were collected at baseline, day 1, day 5, and day 8. No difference in the PRO was observed when nurses or patients applied the patch. PRO data indicated minimal impact on the patient's life. Ease of use, influence on sleep, impact on follow-up of health, or discomfort with continuous monitoring did not change between baseline and day 8. Changes in PRO were observed on day 5, where a 20% (2/10) increase in skin irritation was reported. Withdrawals because of skin irritation were reported in all cases when wearing the second patch. Nurses reported the placement of the VitalPatch to be easy and felt measurements to be reliable.

Conclusions: Generally, the VitalPatch was well tolerated and shown to be an attractive device because of its wearability and low impact on daily activities in patients, therefore making it suitable for implementation in future studies.

Keywords: erythrocyte transfusion; infusions, intravenous; telemedicine; transfusion reaction; wearable electronic devices.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: KL is an employee of physIQ, Inc.

Figures

Figure 1
Figure 1
The accelerateIQ end-to-end solution. IT: information technology.
Figure 2
Figure 2
VitalPatch placement.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Henneman EA, Andrzejewski C, Gawlinski A, McAfee K, Panaccione T, Dziel K. Transfusion-associated circulatory overload: evidence-based strategies to prevent, identify, and manage a serious adverse event. Crit Care Nurse. 2017 Oct;37(5):58–65. doi: 10.4037/ccn2017770. http://ccn.aacnjournals.org/cgi/pmidlookup?view=long&pmid=28966196 - DOI - PubMed
    1. Andrzejewski C, Popovsky MA, Stec TC, Provencher J, O'Hearn L, Visintainer P, Steingrub J. Hemotherapy bedside biovigilance involving vital sign values and characteristics of patients with suspected transfusion reactions associated with fluid challenges: can some cases of transfusion-associated circulatory overload have proinflammatory aspects? Transfusion. 2012 Nov;52(11):2310–20. doi: 10.1111/j.1537-2995.2012.03595.x. - DOI - PubMed
    1. Fagan K, Sabel A, Mehler PS, MacKenzie TD. Vital sign abnormalities, rapid response, and adverse outcomes in hospitalized patients. Am J Med Qual. 2012;27(6):480–6. doi: 10.1177/1062860611436127. - DOI - PubMed
    1. Harrison GA, Jacques TC, Kilborn G, McLaws M. The prevalence of recordings of the signs of critical conditions and emergency responses in hospital wards--the SOCCER study. Resuscitation. 2005 May;65(2):149–57. doi: 10.1016/j.resuscitation.2004.11.017. - DOI - PubMed
    1. Jones DA, DeVita MA, Bellomo R. Rapid-response teams. N Engl J Med. 2011 Jul 14;365(2):139–46. doi: 10.1056/NEJMra0910926. - DOI - PubMed